Craft

Agenus

Stock Price

$10.9

2024-05-17

Market Capitalization

$220.5 M

2024-05-17

Revenue

$156.3 M

FY, 2023

Agenus Summary

Company Summary

Overview
Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer. It develops pharmaceuticals for various types of cancer, tumors, and related diseases and provides target discovery, antibody generation, cell line development, and manufacturing capabilities. The company is also engaged in medical writing, data management, clinical monitoring, program management, and other solutions.
Type
Public
Status
Active
Founded
1994
HQ
Lexington, MA, US | view all locations
Website
https://agenusbio.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Garo H. Armen

    Garo H. Armen, Chairman and Chief Executive Officer

  • Steven O'Day

    Steven O'Day, Chief Medical Officer

  • Alfred Dadson

    Alfred Dadson, Chief Manufacturing Officer

  • Eric Humes

    Eric Humes, Chief Quality Officer

LocationsView all

5 locations detected

  • Lexington, MA HQ

    United States

    3 Forbes Rd

  • Emeryville, CA

    United States

    6455 Christie Ave

  • Berkeley, CA

    United States

  • Vacaville, CA

    United States

  • Cambridge, England

    United Kingdom

    315 Science Park Milton Road

Agenus Financials

Summary Financials

Revenue (Q1, 2024)
$28.0M
Gross profit (Q1, 2024)
$27.9M
Net income (Q1, 2024)
($63.5M)
Cash (Q1, 2024)
$52.9M
EBIT (Q1, 2024)
($32.9M)
Enterprise value
$181.2M

Footer menu